Thursday, 2 December 2021
  
Login

Australia's most trusted
source of pharma news

Thursday, 02 December 2021
News

Immunotherapy drug worry

 Posted 25 November 2021 AM

Australian researchers have found a common medication used to treat reflux, heart burn and ulcers could lessen the effectiveness of lung cancer immunotherapy drugs.

A study by Flinders University, published in Nature's British Journal of Cancer, investigated the impact of proton pump inhibitors (PPIs) on patients undergoing treatment for non-small-cell lung cancer, the most common type of lung cancer, accounting for 85 per cent of cases.

To see the whole article, please login

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.